Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 541,932
  • Shares Outstanding, K 58,524
  • Annual Sales, $ 680 K
  • Annual Income, $ -201,590 K
  • 60-Month Beta 0.67
  • Price/Sales 774.89
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PHAT with:

Options Overview Details

View History
  • Implied Volatility 90.18% ( -59.10%)
  • Historical Volatility 85.70%
  • IV Percentile 21%
  • IV Rank 17.32%
  • IV High 215.46% on 10/27/23
  • IV Low 63.94% on 08/25/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5,255
  • Volume Avg (30-Day) 383
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 3,556
  • Open Int (30-Day) 3,931

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.13
  • Number of Estimates 2
  • High Estimate -1.09
  • Low Estimate -1.16
  • Prior Year -0.89
  • Growth Rate Est. (year over year) -26.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.74 +10.53%
on 04/25/24
12.27 -21.27%
on 04/09/24
-0.14 (-1.43%)
since 04/02/24
3-Month
6.07 +59.27%
on 02/13/24
12.27 -21.27%
on 04/09/24
+2.74 (+39.60%)
since 02/02/24
52-Week
6.07 +59.27%
on 02/13/24
17.02 -43.24%
on 08/11/23
-1.35 (-12.26%)
since 05/02/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches...

PHAT : 9.69 (+4.64%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches...

PHAT : 9.69 (+4.64%)
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom...

PHAT : 9.69 (+4.64%)
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT)...

PHAT : 9.69 (+4.64%)
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom...

PHAT : 9.69 (+4.64%)
PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT)...

PHAT : 9.69 (+4.64%)
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated...

PHAT : 9.69 (+4.64%)
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws

/PRNewswire/ -- Attention Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) shareholders: The Law Offices of Vincent Wong announce that an investigation...

PHAT : 9.69 (+4.64%)
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Phathom...

PHAT : 9.69 (+4.64%)
PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Phathom Pharmaceuticals, Inc. ("Phathom") (NASDAQ: PHAT) violated...

PHAT : 9.69 (+4.64%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 10.13
2nd Resistance Point 9.84
1st Resistance Point 9.55
Last Price 9.69
1st Support Level 8.97
2nd Support Level 8.67
3rd Support Level 8.38

See More

52-Week High 17.02
Fibonacci 61.8% 12.83
Fibonacci 50% 11.54
Fibonacci 38.2% 10.25
Last Price 9.69
52-Week Low 6.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar